aap
Q1/2016 sales and EBITDA in line with expectations - Seite 2
In EUR million |
Q1/2016 | Q1/2015 | Change on year |
Group EBITDA | -1.9 | 0.2 | > -100% |
EBITDA discontinued operation | 0.3 | 2.0 | -85% |
EBITDA continued operation | -2.2 | -1.8 | -23% |
-
Signing of a share purchase agreement for the sale of 100% of the company shares in aap Biomaterials GmbH on 22 March 2016; the transaction was closed on 11 May 2016
-
LOQTEQ®: Progress on schedule in completing the LOQTEQ® product portfolio; focus of research and development activities on implants for lower extremities and the launch of the periprosthetic treatment system
-
Silver coating technology: Submission of design dossier for CE conformity assessment procedure at a notified body in January 2016; first steps in the approval process by the US Food and Drug Administration (FDA) undertaken
Lesen Sie auch
aap Implantate AG is a globally operating medical device company headquartered in Berlin, Germany. The company develops, manufactures and markets trauma and biomaterials products for orthopedics. The trauma portfolio includes besides the innovative anatomical plating system LOQTEQ® a wide range of cannulated screws as well as standard plates and screws. In the biomaterials business the company is specialized on bone cements and mixing systems. In German-speaking countries aap Implantate AG directly sells its trauma products to hospitals, buying syndicates and hospital groups while it uses a broad network of distributors in more than 60 countries at the international level. In the biomaterials business sales are handled via OEM and private label cooperations with several selected international orthopedic and trauma companies. aap Implantate AG's stock is listed in the Prime Standard segment of Frankfurt Stock Exchange (XETRA: AAQ.DE). For more information, please visit www.aap.de, or download the Company's investor relations app from the Apple's App Store or Google Play.